Biomind Labs has completed the development of a novel sublingual formulation to be used in a phase 2 trial for a psychedelic-based candidate for the treatment of depression and anxiety in patients with Alzheimer’s disease.
According to a company press release, Biomind is currently developing novel pharmaceutical formulations of psychedelic molecules 5-Metoxi-N, N-dimethyltryptamine (5-MeO-DMT) and mescaline for the treatment of a wide range of therapeutic indications.
“Our scientific team has completed the challenging development of our proprietary sublingual formulation containing